

Attitudes, Perceptions, and Experiences of Side Effects of COVID-19 Vaccines in Malaysia: Do Age, Gender and Vaccine Type Matter?

Mohamed Hassan Elnaem (✉ drmelnaem@iium.edu.my)

Faculty of Pharmacy, International Islamic University Malaysia <https://orcid.org/0000-0003-0873-6541>

Nor Hidayah Mohd Taufik

Faculty of Pharmacy, International Islamic University Malaysia

Norny Syafinaz Ab Rahman

Faculty of Pharmacy, International Islamic University Malaysia <https://orcid.org/0000-0001-8358-0925>

Nor Ilyani Mohd Nazar

Faculty of Pharmacy, International Islamic University Malaysia

Che Suraya Zin

Faculty of Pharmacy, International Islamic University Malaysia

Wesley Nuffer

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, United States. <https://orcid.org/0000-0002-3355-4582>

Christopher John Turner

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, United States. <https://orcid.org/0000-0001-6547-0896>

Research Article

Keywords: COVID-19, vaccine, Malaysia, attitudes, perceptions, experience, side effects

Posted Date: September 21st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-923374/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Vaccination programs are crucial in global efforts to control the COVID-19 pandemic. Little has been reported regarding the attitudes and experiences of participants in the ongoing Malaysian vaccination program. Therefore, this study aimed to investigate the attitudes, perceptions, and experiences of side effects with the COVID-19 vaccines in Malaysia.

Methods: This study was a cross-sectional survey conducted among vaccine-eligible and vaccinated individuals in Malaysia between May and July 2021. A self-administered 27-item questionnaire was developed and validated before distributing it through an online medium. Descriptive and inferential statistics were performed using SPSS version 22.

Results: A total of 428 respondents completed the survey. More than half of the respondents (71.1%) were 18 to 45 years old, and 66.4% were females. A vast majority (98.6%) of the respondents had registered for the National COVID-19 Vaccination Program. A total of 20 participants (4.7%) expressed their concerns about either registering or receiving the COVID-19 vaccination, and the most reported concern was the uncertainty of vaccine safety. Among the study population, 332 participants (77.5%) received their vaccinations. About 50% received the Pfizer-BioNTech (Cominarty®) vaccine. A majority (76.8%) of the respondents experienced side effects following vaccination. Approximately 40% of the reported side effects occurred more with the second dose, particularly in those who received the Pfizer-BioNTech vaccine ($p < .0005$). Pain at the injection site (61.1%) and tiredness (48.8%) were the most commonly reported side effects. Those who received Sinovac (CoronaVac®) vaccine were more likely to report fewer side effects than Pfizer-BioNTech ($p = .012$) and Oxford-AstraZeneca (ChAdOx1-S) groups ($p = .001$). The logistic regression showed that all age groups, except those aged ≥ 60 years, were more likely to exhibit vaccine-related side effects. Male participants (OR: 0.51, CI:0.27-0.93) and those who received the Sinovac (CoronaVac®) vaccine (OR: 0.08, CI:0.03-0.22) were at lower risk of experiencing vaccine-related side effects.

Conclusions: the overall attitudes toward the national vaccination program were positive, with a vast majority registered to be vaccinated. Several differences in the experiences of vaccine-related side effects in terms of prevalence and number were attributed to age, gender, and received vaccine type.

Introduction

Global efforts to face coronavirus disease 19 (COVID-19) rely primarily on the preventive measures implied by individuals to decrease the likelihood of infection transmission [1]. Consequently, the role of COVID-19 vaccinations in complementing the individual preventive measures to face the pandemic has become vital, and vaccination coverage is regarded as critical for maintaining efficient public health measures [2]. Since the availability of COVID-19 vaccines, governments worldwide have exerted tremendous efforts to execute effective procurement and vaccination programs for individuals [3]. However, with the initiation of vaccination programs at the country level, several issues related to

vaccines' acceptability, effectiveness, and safety have become the focus of community concerns [4]. Consequently, the expected and estimated acceptability rates of vaccines vary across countries. In addition, a significant difference in the efficiency of vaccination programs in terms of coverage of eligible communities and addressing vaccine hesitancy concerns have also been reported [5].

In Malaysia, vaccines have been distributed through the National Vaccination Program to protect Malaysian citizens from vaccine-preventable diseases since the early 1950s. There has been debate in the community about vaccines' permissibility in general, contributing to vaccine hesitancy in some cases [6]. With the extended struggle to control the COVID-19 pandemic, Malaysia has increased its vaccination rate to the point where a total of 21,200,473 doses have been administered, covering 33.2% of the population as of 03/08/2021 [7]. The national COVID-19 vaccination program is considered critical for future societal protection and economic recovery planning. According to previous international reports, vaccine acceptability and hesitancy are influenced by various cultural, societal, and awareness factors [8,9]. Consequently, health care providers have implemented several vaccination advocacy initiatives to raise community awareness regarding the critical role vaccines play in the fight against the COVID-19 pandemic [10].

The National COVID-19 Vaccination Program details the policies, vaccine procurement strategies, implementation efforts, and monitoring necessary to contain the COVID-19 pandemic at the national level [3]. The program was divided into three main phases that were initially planned to cover the entire COVID-19 vaccine-eligible community. Phase 1 of the national vaccination program for COVID-19 has been completed and effectively covered frontliners, including public and private healthcare personnel [3]. Phase 2 has started to cover the remainder of healthcare personnel and senior citizens, while phase 3 is ongoingly dedicated to the remaining eligible residents of the country not covered in the first two phases [3]. With the program's implementation, it is essential to explore people's attitudes, perceptions, and experiences of side effects of their received COVID-19 vaccinations. These findings will be necessary to support the program further and identify the need to foster the success rate of this national initiative [11]. However, little has been reported regarding the attitudes and experiences of COVID-19 vaccinated and vaccine-eligible individuals concurrently with the ongoing national vaccination program. Therefore, this study aimed to investigate the attitudes, perceptions, and experiences of side effects of COVID-19 vaccines in Malaysia.

Methods

Study Design

This study was a cross-sectional survey conducted among vaccine-eligible and vaccinated individuals in Malaysia between May and July 2021.

Study Population and Sample Size

All COVID-19 vaccine-eligible and vaccinated individuals in Malaysia aged 18 and above were accepted to participate in the study, provided that they could read and answer the survey questions either in Malay or English. Children and pregnant women were excluded from this study. Regarding pregnancy, there was no conclusive local evidence to include them as potential candidates at the time of survey planning. However, according to the latest guidelines by the Ministry of Health Malaysia, they are now included as a group suitable for vaccination [12]. According to the Raosoft online sample size calculator (Raosoft, US), assuming a 5% margin of error, 95% confidence level, 50% response distribution, the required sample size for this study was 377.

Ethical Approval

Ethical approval for this study was granted by the IIUM Research Ethics Committee (IREC 2021-200). Participation information sheets and informed consent forms were included in the online survey form. Participants were given the option of withdrawing from the study at any time. Participation was entirely voluntary, with no monetary compensation.

Study Instrument

A self-administered 27-item questionnaire was developed and validated before distributing it to eligible potential participants. A panel of six experts provided inputs to validate the questionnaire. A calculated content validity index (CVI) score of at least 0.83 was achieved for all the finally maintained items. Other items with a CVI of < 0.83 were omitted from the final questionnaire. The final questionnaire consisted of two main parts. Part 1 (19 items) covered primary participants' sociodemographic characteristics, attitudes, and perceptions toward COVID-19 vaccines and the national vaccination program. Meanwhile, part 2 (8 items) covered the experiences of vaccinated individuals regarding the type of received vaccine, experienced side effects and severity, the personal behavior after being vaccinated, and the source of information about COVID-19 vaccines. The questionnaire was designed and distributed via a digital platform.

Statistical Analysis

Descriptive analysis and frequency assessments were applied to the sociodemographic and practice characteristics of the participants. The chi-square test was used to assess the association between nominal variables. In addition, Kruskal-Wallis test was conducted to compare the mean rank scores between different groups of participants. Binomial logistic regression was used to ascertain the effects of specific variables on the likelihood of experiencing vaccine-related side effects. Statistical analysis was performed using SPSS (SPSS, US) version 22.

Results

General information of study participants:

A total of 428 respondents completed the survey. Almost three-fourths of the respondents (71.1%) were 18 to 45 years old. More than half of the respondents (66.4%) were female, and most (85%) were non-smokers. About 50% had a degree or diploma and worked in the public sector (46.7%). The majority (79.2%) reported no chronic diseases, and 70.8% of the respondents had no family members diagnosed with COVID-19 infection. Only 2.8% of respondents had been diagnosed with COVID-19 infection before the vaccine availability. Details of the study participants' information are presented in Table 1.

Table 1: General information of study participants.

	Frequency	Percentage (%)
Age		
18-30	115	26.9
31-45	189	44.2
46-59	68	15.9
60 or more	56	13.0
Race		
Malay	394	92.1
Chinese	14	3.2
Indian	3	0.7
Others	17	4.0
Gender		
Male	144	33.6
Female	284	66.4
Smoking status		
Non-smoker	364	85.0
Ex-smoker	36	8.5
Current smoker	28	6.5
Highest education level		
Doctorate	29	6.8
Masters	62	14.5
Degree/Diploma (Uni/college)	224	52.3
Uni Student	53	12.4
Secondary Edu	58	13.6
Informal Edu	2	0.4
Occupation		
Public sector	200	46.7
Private sector	89	20.8
Self-employed	38	8.9

Unemployed	46	10.8
Student	30	7.0
Pensioner	25	5.8
Chronic diseases		
Yes	89	20.8
No	339	79.2
Having family members/relatives diagnosed with COVID-19 infection?		
Yes	125	29.2
No	303	70.8
Diagnosed with COVID-19 infection before the vaccine availability?		
Yes	12	2.8
No	416	97.2
Total	428	100.0

Vaccination attitudes and adherence to preventive measures among study participants

As shown in Table 2, almost two-thirds (63.3%) of the respondents rated their adherence level to the recommended standard operating procedures (SOP) (e.g., wearing a mask, physical distancing, and regular use of hand sanitizers) as very high. About 99% of the respondents had registered for the National COVID-19 Vaccination Program, with a majority (81.5%) were registered through the MySejahtera application (MySejahtera, Malaysia) [13]. Moreover, more than 80% of all respondents felt highly confident about the effectiveness of COVID-19 vaccines and believed they had received accurate and sufficient information regarding the COVID-19 vaccines (80.1%). Notably, almost all respondents knew that COVID-19 infection could still happen after completing the recommended vaccination dose (97.2%). Also, they knew that the severity of COVID-19 complications of vaccinated patients is lesser than the unvaccinated COVID-19 patients (94.4%).

Table 2. Preventive measures and vaccination attitudes among study participants

	Frequency	Percentage (%)
Please rate your adherence level to the recommended SOP, e.g., wearing a mask, physical distancing, and regular use of hand sanitizers:		
Fair	1	0.2
Good	15	3.5
High	141	32.9
Very high	271	63.3
Total	428	100.0

The National COVID-19 Vaccination Program is currently ongoing. Have you registered to be vaccinated?		
Yes	422	98.6
No	6	1.4
Total	428	100.0

Mode of registration for vaccination:		
MySejahtera App	349	81.5
Employer	63	14.7
Both (App + Employer)	6	1.4
Others (walk-in/Az voluntary program)	6	1.4
Total	424	99.1

Please rate your confidence level regarding the effectiveness of COVID-19 vaccines:		
Low	3	0.7
Fair	6	1.4
Good	53	12.4
High	173	40.4
Very High	193	45.1
Total	428	100.0

Do you believe that you have received accurate and sufficient information regarding the COVID-19 vaccine?		
Yes	343	80.1
No	16	3.7
Not sure	69	16.1

Total	428	100.0
Do you know that COVID-19 infection could still happen after completing the recommended vaccination dose?		
Yes	416	97.2
No	3	0.7
Not sure	9	2.1
Total	428	100.0
Do you know the severity of Covid19 complications to vaccinated Covid19 patients is lesser than unvaccinated Covid19 patients?		
Yes	404	94.4
No	5	1.2
Not sure	19	4.4
Total	428	100.0

Vaccine hesitancy prevalence and reasons:

A total of 20 participants (4.7%) expressed their concerns about registering or receiving the COVID-19 vaccination. The uncertainty regarding vaccine safety was the most common reported reason for vaccine hesitancy (n=7, 35%). Figure 1 shows the percentages of reported reasons for vaccine hesitancy among the study participants.

Vaccine types, side effects, and sources of vaccine-related information

In the present study, among the 428 vaccine-eligible participants, 332 received their vaccination (77.5%). Among the vaccinated respondents, about 50% received the Pfizer-BioNTech (Cominarty®) vaccine, followed by 27.1% Sinovac (CoronaVac®) and 19.3% Astra Zeneca. A majority (76.8%) of respondents experienced side effects following vaccination. Out of 205 respondents, about 40% reported the side effects occurred more with the second dose. Pain at the injection site (61.1%) and tiredness (48.8%) were commonly reported side effects. Figure 2 shows the percentages of the common side effects reported by the study participants. The distribution of the number of side effects reported after the vaccination expressed in percentages is displayed in Figure 3. Most of the respondents (95%) claimed to feel safer after vaccination, but their adherence to SOP remained the same as before vaccinated. The primary source of information regarding the COVID-19 vaccination was from the Ministry of Health and MySejahtera application (53.7%). Other detailed information about vaccines and sources of information are presented in Table 3.

Table 3: Information on vaccine types, side effects, and sources of vaccine-related information.

	Frequency	Percentage (%)
Select the type of vaccine that you have received:		
Pfizer-BioNTech (Cominarty®)	178	53.6
Sinovac (CoronaVac®)	90	27.1
Oxford-AstraZeneca (ChAdOx1-S)	64	19.3
Total	332	100.0
The month you received the COVID-19 vaccine:		
February 2021	3	1.0
March 2021	54	17.6
April 2021	31	10.1
May 2021	39	12.8
June 2021	86	28.1
July 2021	93	30.4
Total	306	100.0
Did you experience any side effects after receiving the vaccine?		
Yes	252	76.8
No	76	23.2
Total	328	100.0
Were the side effects occurred more with the first dose or second dose?		
More with First dose	50	24.4
More with Second dose	80	39.0
No difference	75	36.6
Total	205	100.0
Please rate the severity of the side effects that occurred after vaccination:		
Minor	103	40.9
Mild	69	27.4
Moderate	54	21.4
Moderately severe	24	9.5
Severe	2	.8

Total	252	100.0
Choose the most accurate statement that reflects your adherence to SOP "physical distancing and wearing a face mask" compared to before receiving your vaccine:		
I feel safer removing face mask more frequently compared to before vaccination.	4	1.2
I feel safer, but my adherence to SOP is the same as before vaccination.	305	95.0
I do not feel or practice the SOP related to COVID-19 infection differently.	12	3.8
Total	321	100.0
What is your main source of information regarding the COVID-19 vaccination?		
Official website of Ministry of Health and MySejahtera application.	197	53.7
World Health Organization (WHO).	32	8.7
Social media.	81	22.1
Internet sources such as Google & YouTube.	44	12.0
Family and friends	12	3.2
Peer-reviewed scientific papers	1	.3
Total	367	100.0

Gender and perception on receiving adequate vaccine-related information:

A chi-square test was used to investigate the possible association between gender and the perception of receiving accurate and sufficient vaccine-related information. All expected cell frequencies were greater than five. The results showed a statistically significant association between gender groups and the perception of receiving accurate and sufficient vaccine-related information ($\chi^2(2) = 6.21, p = .045$.)

Types of vaccines, side effects occurrence with first or second doses, number of experienced side effects:

A chi-square test was used to investigate a possible association between the type of received vaccine and the experiencing of vaccine-related side effects after first or second doses. All expected cell frequencies were greater than five. The results showed a statistically significant association between the type of received vaccine and the experiencing of vaccine-related side effects after first or second doses, ($\chi^2(4) = 38.1, p < .0005$.) Moreover, a Kruskal-Wallis H test was run to determine if there were differences in the number of experienced side effects between three groups of received vaccines: the "Pfizer-BioNTech (Cominarty®)", "Sinovac (CoronaVac®)", and "Oxford-AstraZeneca (ChAdOx1-S)" groups. Mean rank scores were statistically significantly different between groups ($H(2) = 13.662, p = .001$). Pairwise comparisons were performed using Dunn's (1964) procedure with a Bonferroni correction for multiple

comparisons. Adjusted p-values are presented. This post hoc analysis revealed statistically significant differences in the number of experienced side effects between the Sinovac group (Mean rank = 92.76) and Pfizer-BioNTech group (Mean rank = 127.54) ($p = .012$) and Sinovac group and Oxford-AstraZeneca group (Mean rank = 144.81) ($p = .001$), but not between the Pfizer-BioNTech and Oxford-AstraZeneca groups.

Logistic regression of age, gender, vaccine type, and the experiencing of vaccine-related side effects:

Binomial logistic regression was performed to ascertain the effects of age, gender, and vaccine type on the likelihood that participants experienced vaccine-related side effects. The logistic regression model was statistically significant, ($\chi^2(6) = 64.85, p < .001$). The model explained 27.5% (Nagelkerke R²) of the variance in experiencing side effects and correctly classified 80.3% of cases. Sensitivity was 94.8%, specificity was 31.1%, positive predictive value was 82.4%, and negative predictive value was 63.8%. Only three predictor variables were statistically significant: age, gender, and vaccine type (as shown in Table 4). All age groups except for the age ≥ 60 years were at increased likelihood of exhibiting vaccine-related side effects. The younger age group (18-30) had 7.4 times higher odds to experience vaccine-related side effects. Male participants (OR: 0.51, CI:0.27-0.93) and those who received the Sinovac (CoronaVac®) vaccine (OR: 0.08, CI:0.03-0.22) were at lower risk of experiencing vaccine-related side effects.

Table 4. Binomial logistic regression of the impact of age, gender, type of received vaccine on the risk of experiencing vaccine-related side effects.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I. for EXP(B)	
							Lower	Upper
Age (18-30)	2.002	.526	14.480	1	.000	7.403	2.640	20.761
Age (31-45)	1.241	.388	10.229	1	.001	3.461	1.617	7.406
Age (46-59)	1.480	.478	9.569	1	.002	4.391	1.720	11.214
Gender (Male)	-.673	.309	4.728	1	.030	.510	.278	.936
Vaccine Type (Pfizer-BioNTech (Cominarty®))	-.805	.503	2.562	1	.109	.447	.167	1.198
Vaccine Type (Sinovac (CoronaVac®))	-2.496	.516	23.382	1	.000	.082	.030	.227
Constant	1.602	.510	9.868	1	.002	4.962		

Discussion

The present study reported the attitude and experiences of Malaysian adults following six months of the National Vaccination Program for COVID-19. The findings showed that the general attitudes towards the ongoing vaccination program were positive. There was a high level of adherence to SOP after being vaccinated. The confidence level in the crucial role of vaccines in facing this pandemic was high. However, there were differences in the experiences of the vaccinated individuals regarding prevalence and number of side effects explained by demographic and vaccine type data.

Out of 428 respondents, the majority (71.1%) were from the younger age group below 45. Although the survey was available in two Malay and English languages, most respondents were Malays (92.1%), which is expected as the major race in Malaysia. With the higher number of female respondents (66.4%), it was expected to have more non-smokers in the survey since most smokers in Malaysia were males [14]. However, it was noted that 6.5% of current smokers have also reported their attitude towards vaccines which is important since they are at higher risk of COVID-19 complications. Furthermore, our findings revealed that approximately 21% of respondents had chronic diseases that may put them at higher risk of COVID-19 infection and complications, implying a need for special care considerations in this patient population [15].

The majority (86%) of the respondents who attended college or university supported the findings that vaccine acceptance was higher in people with higher education levels and higher income [16]. Digital literacy could be one of the factors to this outcome since it is strongly associated with the utility of information and communications technologies among older adults [17]. However, it is essential to note that the national vaccination program has mainly vaccinated health care practitioners, non-health front liners (e.g., police officers), people with comorbidities, and the elderly population until the completion of the present study. It has been proposed that high-risk populations and disadvantaged groups should be prioritized for vaccination while promoting equity and social justice [18].

Most respondents (98.6%) registered for vaccines through the government application *MySejahtera* or their employers. Nevertheless, we need to acknowledge that there were segments in the Malaysian population manually registering at the vaccination centers or lacking internet access and digital literacy. To achieve herd immunity, greater coverage of technology delivering accurate information will reflect collective attitudes and experiences towards vaccines through communication campaigns by the health authorities (Lin et al., 2020). With 32% of respondents having contracted COVID-19 infection or had family members/relatives diagnosed with the disease, these experiences might have influenced our study's positive attitude towards vaccines. Prior to vaccine availability, a study reported that individuals with COVID-19 infection or their family members did not accept vaccines better than others who had no such experiences [16]. Nevertheless, the influence of personal COVID-19 experience toward vaccines was inconclusive [19].

Less than 5% reported concerns about registering or receiving COVID-19 vaccination (Figure 1). The most common concern was related to the vaccine safety reported previously to hinder vaccine uptake to a certain extent [20]. Some other issues were related to the perceived effectiveness of the vaccine, and

willingness to protect others had been reported to influence the acceptance of COVID-19 vaccines [21]. Vaccine hesitancy is a complex global issue involving differences in sociodemographic and external factors, and thus tailored strategies to local intervention must be implemented in the specific population [16,22]. Community intervention has been shown to improve the influenza vaccination rate in specific populations by addressing their concerns [23]. The findings showed a statistically significant difference between males and females on their perception of receiving accurate and sufficient vaccine-related information, where males frequently believed that they did not receive adequate vaccine-related information. This point could be of relevant consideration in the vaccine advocacy initiatives.

Most of our respondents (97.9%) reported good to very high confidence levels towards vaccine effectiveness. However, about one-fifth did not believe that they received accurate and sufficient information regarding COVID-19 vaccines. The main sources of information about COVID-19 vaccination were the official Ministry of Health website and *MySejahtera* application (53.7%), followed by social media (22.1%) and others. Transparency in disseminating vaccines and COVID-19 updates by government health officials is vital to prevent distrust towards vaccines. It has been reported that different countries had different COVID-19 vaccines acceptance rates. However, Malaysia was among the highest (94.3%) other than Ecuador (97.0%), Indonesia (93.3%), and China (91.3%), whereas the lowest acceptance rates were found in Kuwait (23.6%), Jordan (28.4%), Italy (53.7%), Russia (54.9%), Poland (56.3%), US (56.9%), and France (58.9%) [5]. These have also been linked to the level of trust towards information from government sources and employer's advice [16], particularly addressing newly developed vaccines with expedited development or approval with political orientation and interference [19].

Most respondents reported high adherence to standard operating procedures (SOP) to prevent COVID-19 infection. However, a small percentage (8.4%) did not know COVID-19 infection risk following complete vaccination and its severity between vaccinated and unvaccinated individuals. This data indicated that the circulation of the latest information has not effectively reached some communities to control the pandemic effectively. We also found that 1.2% felt safer removing masks frequently after getting vaccinated. In addition, a study reported that people with a positive attitude towards vaccines were more likely to follow strict SOPs than those with negative attitudes [24]. Despite the availability of 13 types of COVID-19 vaccines worldwide with efficacy ranging between 50-95%, preventive behaviors including physical distancing and wearing masks must be continuously enforced by individuals and authorities until effective vaccines are available to overcome the emergence of mutations with coronavirus variants [25]. Health literacy and digital health literacy have been reported independently associated with overall compliance with basic preventive practices [26].

Our respondents received vaccines from three different manufacturing companies, which were Pfizer-BioNTech (Cominarty®) (53.6%), Sinovac (CoronaVac®) (27.1%), and Oxford-AstraZeneca (ChAdOx1-S) (19.3%). Since starting the vaccination program, only 77.5% of respondents have received vaccines, mainly in the last two months (58.5%). The experienced side effects were mainly pain/swelling at the injection site, tiredness, muscle pain, and fever (Figure 2). These were similar to those reported by

previous studies [27]. The side effects tend to be more pronounced with the second dose, especially those who received the Pfizer-BioNTech (Cominarty®) vaccine. These findings could be further explored in the context of vaccine pre-medications to lessen the severity of side effects. The results showed that males, older individuals (≥ 60 years), and those receiving the Sinovac (CoronaVac®) vaccine were less likely to experience side effects. Previous research conducted among health care workers in Turkey reported that females and younger individuals were more likely to report vaccine-related side effects [28]. Also, a previous report during the investigation of mRNA vaccines highlighted those older individuals were less likely to experience the vaccine-related systemic side effects [29].

Interestingly, the number of side effects reported with the Sinovac (CoronaVac®) vaccine was significantly lower than Pfizer-BioNTech and Oxford-AstraZeneca groups. The Sinovac vaccine is an inactivated vaccine, while Pfizer-BioNTech and Oxford-AstraZeneca are nucleic acid and viral vectored vaccines, respectively. Therefore, the differences in the intensity and pattern of side effects could be attributed to the difference in vaccine type as reported previously in comparing potential COVID-19 vaccine candidates [30]. Notably, preliminary reports on the differences between COVID-19 vaccine candidates indicated that Sinovac vaccines might be associated with approximately five times fewer side effects than the other two tested vaccines [30]. Meanwhile, our findings revealed that Sinovac had a 12 times lower correlation with side effects. The side effects after the second dose were more with the Pfizer-BioNTech vaccine, which correlates with the reported data that the systemic side effects of this type of vaccine tend to increase with the second dose [30]. Although several countries have suspended the Oxford-AstraZeneca (ChAdOx1-S) vaccine, especially among younger people, due to reports of vaccine-induced immune thrombocytopenic thrombosis [31], the public in Malaysia has received this vaccine considering the benefits are outweighed the risks of the disease. The majority of respondents had minor/mild side effects, which were similar to what had been reported by previous studies [32,33], but 10.3% experienced moderately severe to severe side effects, which require further investigation.

In Malaysia, the reported incidence of anaphylaxis following vaccination is quite similar to developed countries. The main allergenic ingredients that have caused anaphylaxis were either polyethylene glycol (PEG) or polysorbate 80. Pfizer-BioNTech and Oxford-AstraZeneca vaccines contained PEG and polysorbate 80, respectively whereas, it is not a case for the Sinovac vaccine. Hence, Sinovac has been used as the alternative vaccine in those who have developed anaphylactic reactions with either Pfizer-BioNTech or Oxford-AstraZeneca vaccines [34]. In addition, the Centers for Disease Control have also reported that severe anaphylaxis after the first dose required immediate treatment and monitoring [33]. Other serious side effects reported in previous studies following the second dose were recurrent Bell's Palsy from Pfizer-BioNTech [35] and myocarditis with Moderna [36].

The study is not without limitations. As a survey-based study, it instinctively exposed to a risk of recall bias, especially among those who received their vaccines significantly earlier than the time of data collection. In addition, the absence of extensive details addressing the management of side effects and their duration for specific types of vaccines. Furthermore, the vaccine hesitancy prevalence should be reported carefully as many study participants have received their vaccination. Finally, it is essential to

highlight that the reported severity of side effects was primarily based on individuals' beliefs, not objective measures.

Conclusions

the overall attitudes towards the national vaccination program were positive, with a vast majority registered to be vaccinated. Although vaccine hesitancy was low, the reported concerns must be addressed to ensure a higher success of the vaccination program. There was a high level of adherence to SOP after being vaccinated. The confidence level in the crucial role of vaccines in facing this pandemic was high. However, there were differences in the experiences of the vaccinated individuals regarding prevalence and number of side effects explained by demographic and vaccine type data. Younger age had a higher risk of experiencing side effects than the older population (≥ 60 years). Males had lower odds of developing vaccine-related side effects compared to females. Those who received the Sinovac (CoronaVac®) vaccine had lower odds of experiencing side effects and fewer side effects than the other two vaccine types.

Declarations

Institutional Review Board Statement: Ethical approval for this study was granted by the IIUM Research Ethics Committee (IREC 2021-200). Participation information sheets and informed consent forms were included in the online survey form. Participants were given the option of withdrawing from the study at any time. Participation was entirely voluntary, with no monetary compensation.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Chu, D.K.; Akl, E.A.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H.J.; El-harakeh, A.; Bognanni, A.; Lotfi, T.; Loeb, M.; et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* 2020, *395*, 1973–1987, doi:10.1016/S0140-6736(20)31142-9.
2. Stefanati, A.; d'Anchera, E.; Motoli, F. De; Savio, M.; Toffoletto, M.V.; Gabutti, G. Value of Immunizations during the COVID-19 Emergency. *Int. J. Environ. Res. Public Heal.* 2021, *Vol. 18*, Page 778 **2021**, *18*, 778, doi:10.3390/IJERPH18020778.
3. Ministry of Health (MOH) Malaysia *National Covid-19 Immunisation Programme the Special Committee for Ensuring Access To Covid-19 Vaccine Supply (Jkjav) 18 February 2021*; 2021;
4. Habersaat, K.B.; Jackson, C. Understanding vaccine acceptance and demand—and ways to increase them. *Bundesgesundheitsblatt - Gesundheitsforsch. - Gesundheitsschutz* 2020, *63*, 32–39.

5. Sallam, M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. *Vaccines* 2021, *9*, 1–15.
6. MacDonald, N.E.; Eskola, J.; Liang, X.; Chaudhuri, M.; Dube, E.; Gellin, B.; Goldstein, S.; Larson, H.; Manzo, M.L.; Reingold, A.; et al. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* 2015, *33*, 4161–4164, doi:10.1016/j.vaccine.2015.04.036.
7. Reuter Malaysia: the latest coronavirus counts, charts and maps Available online: <https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/malaysia/> (accessed on Aug 3, 2021).
8. Harapan, H.; Wagner, A.L.; Yufika, A.; Winardi, W.; Anwar, S.; Gan, A.K.; Setiawan, A.M.; Rajamoorthy, Y.; Sofyan, H.; Mudatsir, M. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. *Front. Public Heal.* 2020, *8*, 1–8, doi:10.3389/fpubh.2020.00381.
9. Malik, A.A.; McFadden, S.A.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine* 2020, *26*, 100495, doi:10.1016/j.eclinm.2020.100495.
10. Society, M.P. Immunisation Advocacy Chapter Available online: <https://action=view&retrieveid=7962> (accessed on Jul 14, 2021).
11. Verger, P.; Peretti-Watel, P. Understanding the determinants of acceptance of COVID-19 vaccines: a challenge in a fast-moving situation. *Lancet Public Heal.* 2021, *6*, e195–e196, doi:10.1016/S2468-2667(21)00029-3.
12. Ministry of Health Malaysia *GUIDELINES ON COVID-19 VACCINATION IN PREGNANCY AND BREASTFEEDING*; 2021;
13. Malaysia, M. of H. MySejahtera Available online: <https://mysejahtera.malaysia.gov.my/intro/> (accessed on Aug 11, 2021).
14. Hum, W.L.; Hsien, C.C.M.; Nantha, Y.S. A review of smoking research in Malaysia. *Med. J. Malaysia* 2016, *71*, 29–41.
15. Elnaem, M.H.; Cheema, E. Caring for patients with diabetes during COVID-19 pandemic: Important considerations for pharmacists. *Res. Social Adm. Pharm.* 2020, 0–1, doi:10.1016/j.sapharm.2020.05.030.
16. Lazarus, J. V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. *Nat. Med.* 2021, *27*, 225–228, doi:10.1038/s41591-020-1124-9.
17. Soyeon, S.; Kim, K.-A.; Kim, M.; Oh, J.; Chu, S.H.; Choi, J. Measurement of Digital Literacy Among Older Adults: Systematic Review. *J Med Internet Res* 2021;*23(2)*e26145 <https://www.jmir.org/2021/2/e26145> 2021, *23*, e26145, doi:10.2196/26145.
18. Schmidt, H.; Gostin, L.O.; Williams, M.A. Is It Lawful and Ethical to Prioritize Racial Minorities for COVID-19 Vaccines? *JAMA* 2020, *324*, 2023–2024, doi:10.1001/JAMA.2020.20571.
19. Lin, C.; Tu, P.; Beitsch, L.M. Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. *Vaccines* 2021, *Vol. 9, Page 16* 2020, *9*, 16, doi:10.3390/VACCINES9010016.

20. Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. *Vaccines* 2020, *Vol. 8*, Page 482 2020, *8*, 482, doi:10.3390/VACCINES8030482.
21. Machida, M.; Nakamura, I.; Kojima, T.; Saito, R.; Nakaya, T.; Hanibuchi, T.; Takamiya, T.; Odagiri, Y.; Fukushima, N.; Kikuchi, H.; et al. Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic. *Vaccines* 2021, *Vol. 9*, Page 210 2021, *9*, 210, doi:10.3390/VACCINES9030210.
22. Razai, M.S.; Chaudhry, U.A.R.; Doerholt, K.; Bauld, L.; Majeed, A. Covid-19 vaccination hesitancy. *BMJ* 2021, *373*, doi:10.1136/BMJ.N1138.
23. Tao, L.; Lu, M.; Wang, X.; Han, X.; Li, S.; Wang, H. The influence of a community intervention on influenza vaccination knowledge and behavior among diabetic patients. *BMC Public Heal.* 2019 *191* 2019, *19*, 1–9, doi:10.1186/S12889-019-8101-6.
24. Latkin, C.A.; Dayton, L.; Yi, G.; Colon, B.; Kong, X. Mask usage, social distancing, racial, and gender correlates of COVID-19 vaccine intentions among adults in the US. *PLoS One* 2021, *16*, e0246970, doi:10.1371/JOURNAL.PONE.0246970.
25. Yan, Y.; Pang, Y.; Lyu, Z.; Wang, R.; Wu, X.; You, C.; Zhao, H.; Manickam, S.; Lester, E.; Wu, T.; et al. The COVID-19 Vaccines: Recent Development, Challenges and Prospects. *Vaccines* 2021, *Vol. 9*, Page 349 2021, *9*, 349, doi:10.3390/VACCINES9040349.
26. Patil, U.; Kostareva, U.; Hadley, M.; Manganello, J.A.; Okan, O.; Dadaczynski, K.; Massey, P.M.; Agner, J.; Sentell, T. Health Literacy, Digital Health Literacy, and COVID-19 Pandemic Attitudes and Behaviors in U.S. College Students: Implications for Interventions. *Int. J. Environ. Res. Public Heal.* 2021, *Vol. 18*, Page 3301 2021, *18*, 3301, doi:10.3390/IJERPH18063301.
27. Riad, A.; Pokorná, A.; Attia, S.; Klugarová, J.; Koščík, M.; Klugar, M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. *J. Clin. Med.* 2021, *10*, 1428, doi:10.3390/jcm10071428.
28. Riad, A.; Sağıroğlu, D.; Üstün, B.; Pokorná, A.; Klugarová, J.; Attia, S.; Klugar, M. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. *J. Clin. Med.* 2021, *Vol. 10*, Page 2629 2021, *10*, 2629, doi:10.3390/JCM10122629.
29. Walsh, E.E.; Robert W. Frenck, J.; Falsey, A.R.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Mulligan, M.J.; Bailey, R.; et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <https://doi.org/10.1056/NEJMoa2027906> 2020, *383*, 2439–2450, doi:10.1056/NEJMoa2027906.
30. He, Q.; Mao, Q.; Zhang, J.; Bian, L.; Gao, F.; Wang, J.; Xu, M.; Liang, Z. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. *Front. Immunol.* 2021, *12*, doi:10.3389/FIMMU.2021.669339.
31. Wise, J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. *BMJ* 2021, *372*, n699, doi:10.1136/BMJ.N699.

32. Kadali, R.A.K.; Janagama, R.; Peruru, S.; Malayala, S. V. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. *Int. J. Infect. Dis.* 2021, *106*, 376–381, doi:10.1016/J.IJID.2021.04.047.
33. Centers for Disease Control and Prevention Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine | CDC Available online: <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html> (accessed on Jul 31, 2021).
34. Ministry of Health Malaysia *CLINICAL GUIDELINES ON COVID-19 VACCINATION IN MALAYSIA*; 2021;
35. Repajic, M.; Lai, X.L.; Xu, P.; Liu, A. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy. *Brain, Behav. Immun. - Heal.* 2021, *13*, 100217, doi:10.1016/J.BBIH.2021.100217.
36. Albert, E.; Aurigemma, G.; Saucedo, J.; Gerson, D.S. Myocarditis following COVID-19 vaccination. *Radiol. Case Reports* 2021, *16*, 2142–2145, doi:10.1016/J.RADCR.2021.05.033.

Figures




Figure 1

Percentages of common reasons for hesitancy to register or receive the COVID-19 vaccination




Figure 2

Percentages of commonly reported side effects of the COVID-19 vaccination




Figure 3

Percentages of the number of reported side effects of the COVID-19 vaccination.